Cochrane is pleased to announce the signing of a Partnership Agreement (PA) with the Campbell Collaboration, effective February 2015. The PA provides a framework for the two organizations to work more cooperatively and effectively together in a number of areas of common interest.
We are pleased to announce the publication of the first Cochrane-wide Priority Review List. The creation of this list represents the achievement of a key milestone for Target 1.1 Prioritisation, a part of Cochrane’s Strategy to 2020. In this target we set out to identify about 200 Cochrane reviews, either new titles or reviews requiring updates, that best meet the needs of healthcare and health policy decision makers.
Every Cochrane Review reflects both a substantial commitment of time and expertise on the part of the review author team and all the editors, information specialists and peer reviewers based at the relevant Cochrane Review Group. The work undertaken and the rigour of the process are both focused on ensuring that the best quality evidence from research may inform decision makers.
Cochrane Review shows how a cheaper alternative to licensed drug for treating eye disease has similar side effects
Neovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people globally.
About one in 10 people with macular degeneration suffers legal blindness.
New evidence helps health workers in the fight against Ebola
In a recent story, US-based Fox News discusses the publication of a number of major studies, including a Cochrane Review, assessing aspects of smoking addiction and behaviour, and how the results might be integrated for effective public health intervention.